Current Report Filing (8-k)
30 March 2018 - 5:27AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) of the
SECURITIES
EXCHANGE ACT OF 1934
March
25, 2018
Date
of Report (Date of Earliest event reported)
PetLife
Pharmaceuticals, Inc.
(Exact
Name of Registrant as Specified in Charter)
Nevada
|
|
000-52445
|
|
33-1133537
|
(State
or other Jurisdiction
of
incorporation)
|
|
(Commission
File
Number)
|
|
(IRS Employer
Identification No.)
|
10120
So. Eastern Avenue, Suite 213, Henderson, NV 89052
|
(Address
of principal executive offices)
|
Registrant’s
telephone number, including area code:
|
(855)
682-7853
|
|
|
|
|
(Former
Name or Former Address, If Changed Since Last Report)
|
|
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13c-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (/Section
230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (Section 240.12b-2 of this chapter).
Emerging
growth company [ ]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item
1.01 Entry into a Material Definitive Agreement
Please
see the disclosures set forth under
Item 2.01
below regarding the Transaction (as such term is defined therein) which are
hereby incorporated into this
Item 1.01
by reference.
Item
2.01 Completion of Acquisition or Disposition of Assets.
On
March 25, 2018, PetLife Pharmaceuticals, Inc., a Nevada corporation (the “
Company
”), closed a transaction with
Healthy Life Pets, LLC (“HLP”) (the “
Transaction
”) whereby (i) the Company would return all of
the intellectual property assets that it’s wholly owned subsidiary acquired from HLP pursuant to that certain Asset Purchase
Agreement dated March 10, 2017 (the “Agreement”)(See Exhibit 10.1 to the Company’s Current Report on Form 8-K
filed with the SEC on March 25, 2017) in exchange for (ii) delivery by HLP to the Company, for return to treasury stock, of all
shares of the Company’s Common Stock issued to HLP pursuant to the Agreement.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Current Report on
Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.
Date:
March 29, 2018
|
PETLIFE PHARMACEUTICALS, INC.
|
|
|
|
|
By:
|
/s/
Laura De Leon Castro
|
|
Name:
|
Laura
De Leon Castro
|
|
Title:
|
President
and Chief Executive Officer
|
Petlife Pharmaceuticals (CE) (USOTC:PTLF)
Historical Stock Chart
From Aug 2024 to Sep 2024
Petlife Pharmaceuticals (CE) (USOTC:PTLF)
Historical Stock Chart
From Sep 2023 to Sep 2024
Real-Time news about Petlife Pharmaceuticals Inc (CE) (OTCMarkets): 0 recent articles
More Petlife Pharmaceuticals, Inc. News Articles